Table 3.

Statistical comparison of pharmacokinetic exposure parameters

Test	Reference	Parametera	Adjusted geometric means
			Test	Reference	Ratio (%)b	90 % CI (%)
PF-06439535	Bevacizumab-EU	C max	141.5	135.5	104.42	98.36–110.84
		AUC0–t	40,330	40,490	99.62	93.69–105.93
		AUC0–∞	42,490	43,100	98.58	92.16–105.44
PF-06439535	Bevacizumab-US	C max	141.5	128.9	109.79	103.38–116.60
		AUC0–t	40,330	38,660	104.32	98.06–110.97
		AUC0–∞	42,490	41,120	103.33	96.55–110.58
Bevacizumab-EU	Bevacizumab-US	C max	135.5	128.9	105.15	99.05–111.62
		AUC0–t	40,490	38,660	104.71	98.48–111.34
		AUC0–∞	43,100	41,120	104.82	98.00–112.12

AUC _0–∞ area under the serum concentration–time curve from zero extrapolated to infinity, AUC _0–t area under the serum concentration–time curve from time 0 to the time of the last quantifiable concentration, CI confidence interval, C _max the maximum observed serum concentration

^a C _max, AUC_0–t, and AUC_0–∞ units are measured in μg/mL, μg·h/mL, and μg·h/mL, respectively

^bTest-to-reference ratio of adjusted geometric means